Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2021

04.10.2021 | review

Is thymus and activation-regulated chemokine a forgotten diagnostic and minimal residual disease marker in classical Hodgkin lymphoma?

A chronological narrative literature review

verfasst von: Wael Khair, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Summary

Objective

The objective of this paper is to elucidate the role of thymus and activation-regulated chemokine (TARC) as a marker of treatment response in classical Hodgkin lymphoma (cHL).

Background

Most patients diagnosed with cHL can be cured today but about 20–30% still experience refractoriness/relapse. Positron emission tomography (PET) has been shown to not be the optimal tool, since 15–20% of patients relapse despite negative PET. There is an unmet need for new markers to predict response to treatment as early as possible and for surveillance of patients after completion of treatment to allow prompt intervention in case of signs of evolving relapse.

Methods

Literature regarding the role of thymus and activation-regulated chemokine (TARC) in cHL was searched and 13 studies between 2005 and 2020 with a total of 1433 patients were identified and reviewed.

Conclusion

Reviewed studies suggest that TARC is one of the most promising markers, which can be used to improve treatment outcome in cHL.
Literatur
4.
Zurück zum Zitat Zijtregtop EAM, van der Strate I, Beishuizen A, Zwaan CM, Scheijde-Vermeulen MA, Brandsma AM, et al. Biology and clinical applicability of plasma thymus and activation-regulated chemokine (TARC) in classical Hodgkin lymphoma. Cancers (Basel). 2021;13(4):884. https://doi.org/10.3390/cancers13040884.CrossRef Zijtregtop EAM, van der Strate I, Beishuizen A, Zwaan CM, Scheijde-Vermeulen MA, Brandsma AM, et al. Biology and clinical applicability of plasma thymus and activation-regulated chemokine (TARC) in classical Hodgkin lymphoma. Cancers (Basel). 2021;13(4):884. https://​doi.​org/​10.​3390/​cancers13040884.CrossRef
17.
Zurück zum Zitat Harrison SJ, Hsu AK, Neeson P, Younes A, Sureda A, Engert A, et al. Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. Leuk Lymphoma. 2014;55(5):1053–60. https://doi.org/10.3109/10428194.2013.820287.CrossRefPubMed Harrison SJ, Hsu AK, Neeson P, Younes A, Sureda A, Engert A, et al. Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. Leuk Lymphoma. 2014;55(5):1053–60. https://​doi.​org/​10.​3109/​10428194.​2013.​820287.CrossRefPubMed
18.
Zurück zum Zitat Farina L, Rezzonico F, Spina F, Dodero A, Mazzocchi A, Crippa F, et al. Serum thymus and activation-regulated chemokine level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20(12):1982–8. https://doi.org/10.1016/j.bbmt.2014.08.016.CrossRefPubMed Farina L, Rezzonico F, Spina F, Dodero A, Mazzocchi A, Crippa F, et al. Serum thymus and activation-regulated chemokine level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20(12):1982–8. https://​doi.​org/​10.​1016/​j.​bbmt.​2014.​08.​016.CrossRefPubMed
20.
Zurück zum Zitat Plattel WJ, Alsada ZN, van Imhoff GW, Diepstra A, van den Berg A, Visser L. Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin‑1, sCD163 and sCD30 with TARC. Br J Haematol. 2016;175(5):868–75. https://doi.org/10.1111/bjh.14317.CrossRefPubMed Plattel WJ, Alsada ZN, van Imhoff GW, Diepstra A, van den Berg A, Visser L. Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin‑1, sCD163 and sCD30 with TARC. Br J Haematol. 2016;175(5):868–75. https://​doi.​org/​10.​1111/​bjh.​14317.CrossRefPubMed
24.
Zurück zum Zitat Plattel WJ, Visser L, Diepstra A, Glaudemans AWJM, Nijland M, van Meerten T, et al. Interim thymus and activation regulated chemokine versus interim 18 F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation. Br J Haematol. 2020;190(1):40–4. https://doi.org/10.1111/bjh.16514.CrossRefPubMedPubMedCentral Plattel WJ, Visser L, Diepstra A, Glaudemans AWJM, Nijland M, van Meerten T, et al. Interim thymus and activation regulated chemokine versus interim 18 F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation. Br J Haematol. 2020;190(1):40–4. https://​doi.​org/​10.​1111/​bjh.​16514.CrossRefPubMedPubMedCentral
25.
Metadaten
Titel
Is thymus and activation-regulated chemokine a forgotten diagnostic and minimal residual disease marker in classical Hodgkin lymphoma?
A chronological narrative literature review
verfasst von
Wael Khair, MD
Publikationsdatum
04.10.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00753-x

Weitere Artikel der Ausgabe 4/2021

memo - Magazine of European Medical Oncology 4/2021 Zur Ausgabe